{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/immunizations-pneumococcal/management/children-over-5-years-of-age-adults-diagnosed-at-increased-risk/","result":{"pageContext":{"chapter":{"id":"7f443a07-5081-5296-b56e-8b82550f8c52","slug":"children-over-5-years-of-age-adults-diagnosed-at-increased-risk","fullItemName":"Scenario: Children over 5 years of age and adults diagnosed at increased risk","depth":2,"htmlHeader":"<!-- begin field 2140e929-340e-49c0-a5a0-cfd05a116b0d --><h2>Scenario: Children over 5 years of age, and adults diagnosed at increased risk</h2><!-- end field 2140e929-340e-49c0-a5a0-cfd05a116b0d -->","summary":"Covers the management of people over 5 years of age who are diagnosed at high risk of pneumococcal disease.","htmlStringContent":"<!-- begin item c52b3046-2d20-4260-b758-3052d815af0e --><!-- begin field ca6960f2-e862-47f1-8416-acd900ae19e6 --><p>From age 5 years onwards.</p><!-- end field ca6960f2-e862-47f1-8416-acd900ae19e6 --><!-- end item c52b3046-2d20-4260-b758-3052d815af0e -->","topic":{"id":"af89c4a4-b7c5-5032-9cab-157c542f213b","topicId":"667146c4-e374-494f-a050-b8976e5e7056","topicName":"Immunizations - pneumococcal","slug":"immunizations-pneumococcal","lastRevised":"Last revised in January 2021","chapters":[{"id":"c2a8d969-5d35-5185-b666-883786b066c5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9db009c1-59ed-5d79-9446-33e54e1676c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cf4adec7-88ef-5a0f-b072-53bd3049b260","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5459dd7c-ac40-5828-8bec-840fa7fca764","slug":"changes","fullItemName":"Changes"},{"id":"197178ce-11cd-52df-883c-419e06744dd4","slug":"update","fullItemName":"Update"}]},{"id":"95a44f6b-2987-5086-8656-ef21fcbbc28b","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"006db835-5d01-5085-a6e1-ee57f7ca41c8","slug":"goals","fullItemName":"Goals"},{"id":"29af8dc8-13e9-56c4-a041-b00bbf320b1e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e7b32647-3434-5f3f-b8be-51203e3ebfee","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ebc71bdc-4766-5946-bb16-121b9da544f3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3daf6a12-bce0-53d4-a318-05cc49aab107","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4dce4bc5-1119-5c5d-9422-d275fc956a4e","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"002fbb60-3041-597d-9d3d-fc3a17068591","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"37c59838-49d0-51d5-8203-1eae848738c2","slug":"definition-of-pneumococcal-disease","fullItemName":"Definition of pneumococcal disease"},{"id":"aba9a3c5-f0f7-5e65-b369-1947461d0158","slug":"prevalence-of-pneumococcal-disease","fullItemName":"Prevalence of pneumococcal disease"},{"id":"9da9e662-ccc4-5bc4-bae8-eb3f0ec80b19","slug":"risk-factors-for-pneumococcal-disease","fullItemName":"Risk Factors for pneumococcal disease"},{"id":"492f20c5-5e03-51dc-9ccb-1994f3db1c35","slug":"pneumococcal-immunization","fullItemName":"Pneumococcal immunization"}]},{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","fullItemName":"Management","slug":"management","subChapters":[{"id":"b036915e-0e64-5fea-a247-9777822304b3","slug":"routine-vaccination-of-infants-adults-over-65-years-of-age","fullItemName":"Scenario: Routine vaccination of infants, and adults over 65 years of age"},{"id":"8f83b7e0-d764-5bca-a03b-e549e24f402a","slug":"children-diagnosed-at-increased-risk-under-2-years-of-age","fullItemName":"Scenario: Children diagnosed at increased risk under 2 years of age"},{"id":"c9787edf-835f-54d9-9b86-b7c8695307ef","slug":"children-diagnosed-at-increased-risk-aged-2-5-years","fullItemName":"Scenario: Children diagnosed at increased risk aged 2-5 years"},{"id":"7f443a07-5081-5296-b56e-8b82550f8c52","slug":"children-over-5-years-of-age-adults-diagnosed-at-increased-risk","fullItemName":"Scenario: Children over 5 years of age and adults diagnosed at increased risk"}]},{"id":"f17e101b-7bea-59aa-9b9c-46924bbfdc2b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"871f5861-588e-57ef-9521-0a81e77d4583","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d0a50959-6448-5a18-8845-f75f5c40f388","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92b33782-e97b-565d-b432-b19376ecedbc","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5b1e27f9-71f0-5238-978b-5648b601e292","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2b6c5d09-7606-5742-89c4-19fa3b671fd7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"037af05f-e510-5862-b316-4676f7c3a61e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"04bd9328-ed11-5b9d-ba9a-06584ecd6f33","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e183f01f-d538-542b-bc16-6f849966d1d2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"b5e5fbcc-b5e1-5759-8575-d165007ba054","slug":"children-over-5-years-adults","fullItemName":"Children over 5 years, and adults","depth":3,"htmlHeader":"<!-- begin field 599cf2c5-3d10-482e-85d2-bfaa054b6f02 --><h3>How should I vaccinate children over 5 years of age, and adults diagnosed at increased risk?</h3><!-- end field 599cf2c5-3d10-482e-85d2-bfaa054b6f02 -->","summary":null,"htmlStringContent":"<!-- begin item 404157cf-5748-4b04-8e96-b170600ddb12 --><!-- begin field 82c9fed4-b6e4-4187-a77a-04dc0810e21b --><ul><li><strong>People at increased risk of pneumococcal disease or complications include those with:</strong><ul><li>Asplenia or splenic dysfunction.</li><li>Chronic respiratory, heart, kidney, or liver disease.</li><li>Diabetes requiring insulin or oral hypoglycaemic drugs.</li><li>Immunosuppression due to a medical condition or treatment.</li><li>Cochlear implants.</li><li>Cerebrospinal fluid leaks (including leakage following trauma or major skull surgery).</li><li>Occupational risks (including welders).<ul><li>For more details, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/background-information/risk-factors-for-pneumococcal-disease/\">Risk factors</a>.</li></ul></li></ul></li><li><strong>Offer people over the age of 5 years who are diagnosed at increased risk of pneumococcal disease but without significant immunosuppression,</strong> a single dose of the 23-valent pneumococcal polysaccharide vaccine (PPV23) (Pneumovax<sup>®</sup>). Re-vaccination is not required for people in this group.</li><li><strong>Offer people </strong><strong>over the age of 5 years who are diagnosed at increased risk of pneumococcal disease</strong> <strong>and</strong> <strong>who are severely immunocompromised</strong> (including bone marrow transplant recipients, people with acute and chronic leukaemia, multiple myeloma, or genetic disorders affecting the immune system) a single dose of the 13-valent pneumococcal conjugate vaccine (PCV13) (Prevenar 13<sup>®</sup>), followed by PPV23 after a period of at least 2 months (irrespective of their routine immunizations).<ul><li>For people with leukaemia, PCV13 should be given from 6 months after completion of chemotherapy, and for people with bone marrow transplants, PCV13 should be offered 9–12 months after transplantation.</li><li>Severely immunocompromised people who have already received PPV23 should wait at least 6 months before receiving PCV13.</li><li>Unvaccinated children and adults undergoing splenectomy or commencing immunosuppressive treatment should ideally be vaccinated 4–6 weeks beforehand, according to the schedule for their specific risk group. However, if it is not possible to vaccinate beforehand, treatment should not be delayed.</li></ul></li><li><strong>For people with asplenia, splenic dysfunctinon, or chronic kidney disease, re-vaccination with PPV23 is recommended every 5 years.</strong></li><li>Pneumococcal vaccines can be given to pregnant or breastfeeding women when the need for protection is required without delay.</li><li>If the person presents without a reliable immunization history, it should be assumed that they have not been vaccinated.</li></ul><!-- end field 82c9fed4-b6e4-4187-a77a-04dc0810e21b --><!-- end item 404157cf-5748-4b04-8e96-b170600ddb12 -->","subChapters":[{"id":"e94923b4-2aef-51cc-8c21-587517f81afb","slug":"basis-for-recommendation-f22","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 40d1c451-643d-4519-8a89-4d56f4835b04 --><h4>Basis for recommendation</h4><!-- end field 40d1c451-643d-4519-8a89-4d56f4835b04 -->","summary":null,"htmlStringContent":"<!-- begin item f22f32bf-a73f-4e23-8cf1-0e07000e7665 --><!-- begin field 8661c808-af35-4b99-8164-9183b085f85a --><p>The recommendations on pneumococcal immunization are based government policy as discussed in Chapter 25 of <em>Immunisation against infectious disease</em> (the 'Green Book'), published by the Department of Health [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013a</a>].<br> </p><!-- end field 8661c808-af35-4b99-8164-9183b085f85a --><!-- end item f22f32bf-a73f-4e23-8cf1-0e07000e7665 -->","subChapters":[]}]},{"id":"12d38c48-7fb0-5a2b-95cc-8821f26c00fd","slug":"what-advice-should-i-give","fullItemName":"What advice should I give?","depth":3,"htmlHeader":"<!-- begin field 96735f7b-ab45-40cb-828c-964e80905055 --><h3>What advice should I give?</h3><!-- end field 96735f7b-ab45-40cb-828c-964e80905055 -->","summary":null,"htmlStringContent":"<!-- begin item 11189432-bc30-4420-8505-dca40e8a0d9a --><!-- begin field 65d87a4b-d807-4ef6-9742-2f82c7c51f7f --><ul><li><strong>Explain the benefits of vaccination to the person, or their parent or carer,</strong> in particular that it helps prevent serious illness, including meningitis in young children. <ul><li>Information about vaccinations (including vaccine safety, risks and benefits, and individual vaccines) is available on the NHS website at <a style=\"background-color: #ffffff;\" href=\"http://www.nhs.uk/pages/home.aspx\" data-hyperlink-id=\"b84f4290-7c42-4fdf-ad0d-a98d00039ce3\">www.nhs.uk</a>.</li></ul></li><li><strong>Reassure that vaccinations are safe, and serious adverse effects are very rare.</strong> Pain, swelling, and reddening at the site of injection are most common and systemic adverse effects, should they occur, are usually limited to mild fever.</li><li><strong>If pain or fever is problematic after the person has been vaccinated, then paracetamol or ibuprofen may be used.</strong> For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li><li><strong>Offer parents or carers written information,</strong> such as the Public Health England patient information leaflets <a href=\"https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448789/8584-what-to-expect-after-vaccination-2015-2P-A5-02-web.pdf\" data-hyperlink-id=\"69a9fa97-50c4-41dc-80fe-a98d00039cfe\">What to expect after vaccinations</a>.</li></ul><!-- end field 65d87a4b-d807-4ef6-9742-2f82c7c51f7f --><!-- end item 11189432-bc30-4420-8505-dca40e8a0d9a -->","subChapters":[{"id":"07bb0615-1e46-5ce6-b68d-ee0e44dfe700","slug":"basis-for-recommendation-1e1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fdb10eed-6488-4767-af34-a8318d5344e0 --><h4>Basis for recommendation</h4><!-- end field fdb10eed-6488-4767-af34-a8318d5344e0 -->","summary":null,"htmlStringContent":"<!-- begin item 1e1c218d-d0f6-4e97-adb2-d399f7215751 --><!-- begin field b0433aaa-7179-4c97-b47c-312ebf3d7970 --><p>The recommendations on advice to give about pneumococcal immunization are based on information in the chapter on vaccine safety and adverse effects following immunization in <em>Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>] , and are pragmatic, based on what CKS considers to be good clinical practice.</p><h5>Explaining the benefits of vaccination</h5><ul><li>Many parents find the process of having their children immunized distressing. Explaining the benefits of vaccination and giving reassurance about the limited nature of any adverse effects should be helpful.</li></ul><h5>Using paracetamol or ibuprofen</h5><ul><li>CKS found no controlled trials on the efficacy of paracetamol or ibuprofen in reducing pain or fever following vaccination. As paracetamol and ibuprofen have been shown to reduce fever and pain in conditions such as the common cold and influenza [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Eccles, 2006</a>], it can be reasonably extrapolated that they may be effective in relieving these symptoms on an 'as required' basis after vaccination. </li><li>PHE recommends that paracetamol or ibuprofen should not be given to prevent fever in children who receive pneumococcal vaccinations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>]. It states that there is no evidence that paracetamol or ibuprofen prevent febrile convulsions and that there is some evidence that they may lower antibody responses to some vaccines when given around the time of vaccination [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">Prymula et al, 2009</a>].</li></ul><!-- end field b0433aaa-7179-4c97-b47c-312ebf3d7970 --><!-- end item 1e1c218d-d0f6-4e97-adb2-d399f7215751 -->","subChapters":[]}]},{"id":"f5db4604-671d-5e95-9556-ce66c517ee20","slug":"how-to-administer-the-vaccine","fullItemName":"How to administer the vaccine","depth":3,"htmlHeader":"<!-- begin field 4b8407ce-e6e3-4869-a446-4641ec3e92b9 --><h3>How to administer the vaccine</h3><!-- end field 4b8407ce-e6e3-4869-a446-4641ec3e92b9 -->","summary":null,"htmlStringContent":"<!-- begin item 7e0ea1b2-d058-40d2-af2d-eb3f7429e36e --><!-- begin field f3b921c8-fb04-419a-a368-34e2ea39651b --><ul><li><strong>Obtain written or verbal consent at the time of vaccination for people aged over 16 years. For younger people it is usual to get consent from a person with parental responsibility.</strong><ul><li>Adults over 18 years of age are presumed to be competent to consent to treatment provided they can comprehend and retain the information they are given, and they can consider the facts and make an informed decision.</li><li>Young people of 16 and 17 years of age are also presumed to be competent using the same criteria as older adults.</li><li>Younger people can also give consent if they fully understand what is involved, but ideally a person with parental responsibility should also be involved.</li></ul></li><li><strong>Ensure that:</strong><ul><li>There are no contraindications to the vaccine.<ul><li>The only absolute contraindication to pneumococcal vaccination is a confirmed previous anaphylactic reaction to the vaccine or one of its components.</li></ul></li><li>The person, parent, or carer has been fully informed about the vaccine and the vaccination procedure.</li><li>Possible adverse reactions have been discussed and the person, parent, or carer is aware of how to manage them. </li><li>The vaccine is correct, has been stored appropriately, and has not expired. </li><li>The vaccination site has been washed with soap and water if it is visibly dirty. </li></ul></li><li><strong>For people who are acutely unwell (for example if the person has a fever or acute infection), postpone pneumococcal immunization until they have fully recovered.</strong> Minor illness without fever or systemic upset is not a valid reason to postpone immunization.</li><li><strong>Pneumococcal vaccines are usually given by intramuscular (IM) injection, into the upper arm in children and adults.</strong><ul><li>Use a 25mm 23-gauge (blue) or 25-gauge (orange) needle for IM administration in children and most adults.</li><li>In larger adults, a longer length (such as 38mm) may be required.  </li></ul></li><li><strong>Pneumococcal vaccines can be given at the same time as other vaccines.</strong> If an additional vaccine is required on the same day, use separate limbs if possible, or inject at sites at least 2.5 cm apart. </li><li><strong>Record the date of administration, vaccine and product name, batch number, expiry date, dose administered, and site of administration for each vaccine.</strong> </li><li><strong>Observe the person after vaccination to detect immediate adverse reactions.</strong> Ensure any bleeding has stopped and check for any symptoms of anaphylaxis before they leave.<ul><li>Anaphylaxis is extremely rare, and usually becomes apparent within minutes. By the time the site has been checked for bleeding and documentation has been completed, most reactions will have become apparent. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li></ul></li></ul><!-- end field f3b921c8-fb04-419a-a368-34e2ea39651b --><!-- end item 7e0ea1b2-d058-40d2-af2d-eb3f7429e36e -->","subChapters":[{"id":"5876d4a3-0c52-5130-a608-f00d1333db43","slug":"basis-for-recommendation-ee3","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fd1eeba5-bc8c-47d7-b41e-efad269bb02d --><h4>Basis for recommendation</h4><!-- end field fd1eeba5-bc8c-47d7-b41e-efad269bb02d -->","summary":null,"htmlStringContent":"<!-- begin item ee3414cf-faa2-4af2-b55c-7ba9d989b49e --><!-- begin field 48e97016-163a-48bc-a63a-62171881e70f --><p>These recommendations are based on chapters in <em>Immunisation against infectious disease</em> (the 'Green Book') published by Public Health England (PHE)  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013b</a>], and what CKS considers to be good clinical practice.</p><h5>Obtaining consent</h5><ul><li>Consent for immunizations does not legally have to be in writing, but must be given voluntarily by a fully informed person who is able to make and communicate their decision. For children not competent to give or withhold consent, a person with parental responsibility can provide this [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013c</a>].</li></ul><h5>Site of administration</h5><ul><li>In people over the age of 1 year, vaccines are routinely given into the deltoid muscle as it is convenient, providing easy access, and it reduces the risk of localized reactions, which are common when vaccines are given subcutaneously.</li><li>The gluteal muscle should be avoided. The needle may not penetrate through adipose tissue into the muscle, and this may cause a poor immunological response to the vaccine. In addition, there is a risk of damage to underlying structures such as the sciatic nerve [<a class=\"bibliography-reference internal-reference\" href=\"/topics/immunizations-pneumococcal/references/\">PHE, 2013d</a>].</li></ul><!-- end field 48e97016-163a-48bc-a63a-62171881e70f --><!-- end item ee3414cf-faa2-4af2-b55c-7ba9d989b49e -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}